local_hospital

Carl-von-Basedow-Klinikum Saalekreis gGmbH

Address
lock Available on a paid plan

Neurology and Stroke Research

At Carl-von-Basedow-Klinikum Saalekreis gGmbH in Merseburg, clinical research in nervous system diseases focuses on serious emergency conditions such as acute ischemic stroke and status epilepticus in older adults. These studies are designed to evaluate new treatment options and generate evidence for better care in time-critical neurological conditions.

  • Testing a new therapy for acute ischemic stroke to assess safety and potential benefit
  • Studying treatment effectiveness for established status epilepticus in people aged 65 and older

This work aims to improve outcomes in high-risk neurological emergencies through better treatment strategies and clinical evidence.

Oncology Research

Clinical trials in neoplasms at this hospital are centered on difficult-to-treat cancers, especially advanced colorectal carcinoma. The research is evaluating whether adding a new supportive treatment approach can improve disease control and help patients whose cancer no longer responds well to standard therapy.

  • Assessing treatment effectiveness in metastatic colorectal carcinoma
  • Exploring a new combination approach to improve tumor control in chemotherapy-resistant disease

The Medizinische Klinik II contributes to studies that aim to refine cancer care for patients with advanced disease.

Hematology and Rare Disease Studies

Research also includes polycythemia vera, a chronic blood disorder within the broader area of neoplasms. One study is focused on identifying patients at risk of hydroxyurea resistance or intolerance, using predictive factors to support more personalized treatment decisions.

  • Evaluating hydroxyurea resistance in polycythemia vera
  • Using predictive tools to improve treatment planning for patients starting regular therapy

This line of research reflects an effort to improve long-term management of a complex hematologic condition through earlier identification of treatment challenges.

Site Overview

assignment
4
connected trials
corporate_fare
4
sponsors
science
8
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
4
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
4
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
4
Outperforms 67% of sites
public
Therapeutic diversity
2areas
Outperforms 62% of sites
groups
Sponsor diversity
4sponsors
Outperforms 71% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Carl-von-Basedow-Klinikum Saalekreis gGmbH

lock Showing 1 of 4 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)Lumosa Therapeutics Co. Ltd.Phase IINot RecruitingDec 2023May 2025

IMP list

lock Showing 1 of 8 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil1Unknown2025-02-252025-02-25

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.